Ticker Hub
REGN — AI Analysis & Sentiment
8 recent AI-generated analyses for REGN. Sentiment and confidence insights updated continuously.
Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis
Regeneron's Lynozyfic demonstrated compelling Phase 1/2 results for AL amyloidosis, showcasing near 100% complete response rates in an area of high...
May 21, 2026Dupixent® (dupilumab) Demonstrates Improved Esophageal Function in Eosinophilic Esophagitis (EoE) Phase 4 Trial
Regeneron's Dupixent demonstrated strong Phase 4 results, confirming improved esophageal function in EoE and reinforcing its market position. This ...
May 5, 2026Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
Regeneron secured a strategic agreement with the U.S. government, exchanging some drug pricing flexibility for critical regulatory relief and futur...
Apr 23, 2026Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
Regeneron's FDA approval for Otarmeni, its first gene therapy, is a strategic win validating a new platform despite limited immediate revenue from ...
Apr 23, 2026Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
Regeneron's Dupixent received FDA approval for chronic spontaneous urticaria in young children, opening a new market for the drug. This regulatory ...
Apr 22, 2026Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite Treatment
European regulators recommended Dupixent for pediatric chronic urticaria, expanding its market for a key drug. This positive regulatory step could ...
Feb 27, 2026Dupixent® (dupilumab) Approved in the U.S. as the First and Only Medicine for Allergic Fungal Rhinosinusitis (AFRS)
FDA approval for Dupixent in AFRS expands the market for this blockbuster drug, strengthening Regeneron's long-term revenue outlook. The lack of po...
Feb 24, 2026Garetosmab Biologics License Application Accepted for FDA Priority Review for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)
FDA's Priority Review for Regeneron's garetosmab significantly de-risks a potential first-in-class treatment for a rare disease, adding substantial...
Feb 19, 2026